BetaSCREEN: platform for drug screening in diabetes

Project Details

Description

BETA-CELL is a privately owned biopharmaceutical company that develops novel cell therapy and other products related to Diabetes.

The company is a spin-off from the Brussels Free University - Diabetes Research Center (VUB-DRC), established in 1998. The DRC is a leader in the biology of insulin-producing beta cells and its use as platform for novel methods in the diagnosis and treatment of diabetes. It has particular expertise in cell isolation and quality control, stem/precursor cell characterization and differentiation, preparation of standardized beta cell grafts and organization and funding of multi-center clinical trials in diabetes patients.

DRC is an internationally recognized center of excellence in the field of diabetes. BETA-CELL's technology platform is based on prior, current and future work at the DRC. It has acquired proprietary technology for a first product line, with BetaGRAFT as a lead, and has an agreement on its first right of refusal on all diabetes related Intellectual Property (IP) generated at DRC.

Recent developments have opened a second line in the field of beta cell regeneration, with BetaREG as a lead, and a third one in the field of drug screening and discovery, defined as BetaSCREEN
Short title or EU acronymBetaSCREEN
AcronymIWT556
StatusFinished
Effective start/end date1/04/1331/03/14

Flemish discipline codes

  • Basic sciences
  • Biological sciences

Keywords

  • Cell Therapy
  • Prevention
  • Transplantation
  • Diagnostic Tests
  • Immunology
  • Cell Death and Survival
  • Islet Cell Pathology
  • Islet Cell Biology
  • Beta Cell Transplantation
  • Diabetes